Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Shenzhen Chipscreen Biosciences.

    Client Virtual Booth

    SHENZHEN CHIPSCREEN BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Shenzhen Chipscreen Biosciences
    China Flag
    Country
    Country
    China
    Address
    Address
    Rooms 601-606, Building 2, Hi-tech Incubator Building, High-tech No. 1 Road, Nanshan District Science Park, Shenzhen
    Telephone
    Telephone
    +86-0755-26957330
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.chipscreen.com/en/index.php/shouye
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Positive Results from Phase II Clinical Trial (CGZ203 study) of Chiglitazar Monotherapy for Non-Alcoholic Steatohepatitis

    Details:

    Bilessglu (chiglitazar sodium) is a novel peroxisome proliferator activation-related receptor pan-agonist, which is being evaluated for the treatment of non-alcoholic steatohepatitis.


    Lead Product(s): Chiglitazar Sodium

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Bilessglu

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 18, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanc...

    Details:

    NWY001 is world's first PD-1/CD40 bispecific antibody. It is currently being evaluated in phase 1 clinical trials for the treatment of patients with advanced solid tumors.


    Lead Product(s): NWY001

    Therapeutic Area: Oncology Product Name: NWY001

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 16, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

    Details:

    CS32582 is a novel small molecule and highly selective allosteric inhibitor of Tyrosine Kinase 2 (TYK2). It got approval for conducting clinical trials for the treatment of psoriasis.


    Lead Product(s): CS32582

    Therapeutic Area: Dermatology Product Name: CS32582

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 02, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in Japan

    Details:

    Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.


    Lead Product(s): Chidamide

    Therapeutic Area: Oncology Product Name: HBI-8000

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: HUYA Bioscience International

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chipscreen Received a Phase 1b/2 Clinical Trial of Chiauranib/CS2164 IND Clearance from the US Food and Drug Administration (FDA)

    Details:

    Chiauranib is an innovative, 3-pathway targeted kinase small molecule inhibitor with high selectivity against Auroa B /VEGFRs/CSF1R currently entering Phase III clinical trials in China.


    Lead Product(s): Chiauranib

    Therapeutic Area: Oncology Product Name: CS2164

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

    Details:

    CS12192 showed significant efficacy in multiple autoimmune disease models in preclinical studies.


    Lead Product(s): CS12192

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 24, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search